Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens

Published:2021-02-17 Issue:3 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Nguyen T.¹,Oualha M.¹²,Briand C.³,Bendavid M.²,Béranger A.¹²,Benaboud S.¹⁴,Tréluyer J.-M.¹⁴⁵⁶,Zheng Y.¹⁴,Foissac F.¹⁵⁶,Winter S.³,Gana I.¹⁴,Boujaafar S.¹⁴,Lopez V.⁷,Berthaud R.¹⁶⁸,Demir Z.⁹,Bouazza N.¹⁵⁶,Hirt D.¹⁴¹⁰^ORCID

Affiliation:

1. EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, Paris, France

2. Service de Réanimation et Surveillance Continue Médico-Chirurgicales Pédiatriques, Hôpital Necker Enfants Malades, Paris, France

3. Service d’Hématologie, Immunologie et Rhumatologie Pédiatrique, Hôpital Necker Enfants Malades, Paris, France

4. Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France

5. Unité de Recherche Clinique Paris Descartes Necker Cochin, AP-HP, Paris, France

6. CIC-1419 Inserm, Cochin-Necker, Paris, France

7. Service de Réanimation Cardiaque Pédiatrique, Hôpital Necker Enfants Malades, Paris, France

8. Service de Néphrologie Pédiatrique, Hôpital Necker Enfants Malades, Paris, France

9. Service de Gastro-Entérologie, Hépatologie et Nutrition Pédiatriques, Hôpital Necker Enfants Malades, Paris, France

10. INSERM, U1018, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France

Abstract

Ganciclovir is indicated for curative or preventive treatment of cytomegalovirus (CMV) infections. This study aimed to characterize ganciclovir pharmacokinetics, following intravenous ganciclovir and oral valganciclovir administration, to optimize dosing schemes.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02254-20

Reference24 articles.

1. Agence nationale de sécurité du médicament et des producits de santé. 2019. Ganciclovir - résumé des caractéristiques du produit. ANSM Saint Denis France.

2. Agence nationale de sécurité du médicament et des producits de santé. 2019. Valganciclovir - résumé des caractéristiques du produit. ANSM Saint Denis France.

3. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients

4. Reference deleted.

5. Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of patients’ characteristics associated with the efficacy and safety of oral valganciclovir treatment for infants with symptomatic congenital cytomegalovirus disease;Journal of Infection and Chemotherapy;2024-10

2. Pharmacokinetic and Pharmacodynamic Assessment of Valganciclovir in Infants With Congenital Cytomegalovirus Infection;Therapeutic Drug Monitoring;2024-09-04

3. Application of machine-learning models to predict the ganciclovir and valganciclovir exposure in children using a limited sampling strategy;Antimicrobial Agents and Chemotherapy;2024-08-28

4. Initial dosage optimization of olanzapine in patients with bipolar disorder based on model-informed precision dosing: a study from the real world;Frontiers in Pharmacology;2024-08-21

5. Optimization of Ganciclovir and Valganciclovir Starting Dose in Children by Machine Learning;Clinical Pharmacokinetics;2024-03-16